[The medical treatment strategy of secondary hyperparathyroidism use of vitamin D in Europe and America].
The medical treatment strategies of vitamin D appeared in the guideline of K/DOQI (Kidney Disease Outcomes Quality Initiative) in the U.S. and Clinical algorithms on renal osteodystrophy in Europe. The target intact PTH value is 150-300 pg/mL (16.5-33.0 pmol/L) in U.S. and 9-18 pmol/L (82-164 pg/mL ) in Europe. It was set up more highly in U.S. than in Europe. A European and American medical treatment strategies are not so different from that of Japan in the routes and metabolites of vitamin Ds.
Miwa
Naoko
N
Department of Medicine, Kidney Center, Tokyo Women's Medical University.
Akiba
Takashi
T
D000465:Algorithms; D015415:Biomarkers / Q000097:blood; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000150:complications / Q000188:drug therapy; D005060:Europe; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D010281:Parathyroid Hormone / Q000097:blood; D017410:Practice Guidelines as Topic; D014481:United States; D014807:Vitamin D / Q000008:administration & dosage* / Q000031:analogs & derivatives
D015415:Biomarkers; D010281:Parathyroid Hormone; D014807:Vitamin D